Sarepta治疗公司面临证券欺诈诉讼, 指控其基因疗法安全性存在误报。 Sarepta Therapeutics faces a securities fraud lawsuit over alleged misstatements on its gene therapy's safety.

Levi & Korsinsky代表2023年6月22日至2025年6月24日期间购买证券的股东对Sarepta The治疗公司提起了证券欺诈集体诉讼。 A securities fraud class action lawsuit has been filed against Sarepta Therapeutics by Levi & Korsinsky on behalf of shareholders who purchased securities between June 22, 2023, and June 24, 2025. 诉讼声称,该公司就其基因疗法ELEVIDYS作了虚假陈述,并隐瞒了安全风险,导致停止审判和强化监管监督。 The lawsuit alleges that the company made false statements and concealed safety risks regarding its gene therapy ELEVIDYS, leading to halted trials and increased regulatory scrutiny. 遭受损失的股东可以通过诉讼寻求补偿。 Shareholders who suffered losses can seek compensation through the lawsuit. 已经对Capricor治疗和火箭制药公司提出了类似的诉讼,指控它们关于治疗的误导性言论。 Similar lawsuits have been filed against Capricor Therapeutics and Rocket Pharmaceuticals for alleged misleading statements about their therapies.